Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LGMN | Q99538 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9413151 | 0.88 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16648747 | 0.88 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6871006 | 0.85 | KMT2A (0.74) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16880258 | 0.85 | LGMN (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22368269 | 0.82 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16648472 | 0.82 | MAPT (0.54) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16769737 | 0.82 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL321187 | 0.82 | LMNA (0.65) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4389854 | 0.80 | MAPT (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1442632 | 0.80 | HRH3 (0.57) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862861-B1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150575-B2 | Piperidinylpyrazolopyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2862861-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2590963-B1 | (3-METHYLPYRROLIDIN-3-YL)METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2590963-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012004207-A1 | (3 -METHYLPYRROLIDIN- 3 - YL) METHYL PYRIDINYL ETHER DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | MEN1 4760/4885KMT2A 888/4885SMN1; SMN2 1784/4885 |
| US-20120010212-A1 | METHYL-PYRROLIDINE ETHER DERIVATIVES | OPRM1, OPRK1, OPRD1 | MEN1 4677/4885KMT2A 422/4885SMN1; SMN2 796/4885 |
| US-20150152102-A1 | PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE | LCAT, LPL, LCLAT1 | MEN1 4861/4885KMT2A 1626/4885SMN1; SMN2 1535/4885 |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | MEN1 4760/4885KMT2A 888/4885SMN1; SMN2 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.